PTCTPTC Therapeutics, Inc.

$6B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.2B+459.7% YoY

Gross Profit

$1.2B98.9% margin

Operating Income

$970M82.5% margin

Net Income

$867M73.7% margin

EPS (Diluted)

$10.04

QoQ Revenue Growth

+451.7%

Cash Flow

Operating Cash Flow

$870M

Free Cash Flow

$868M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$2.8B

Stockholders' Equity

-$186M

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$210M	+459.7%
Gross Profit	$1.2B	$195M	+495.4%
Operating Income	$970M	-$45M	+2234.6%
Net Income	$867M	-$92M	+1046.3%

Revenue Segments

Collaboration and License Revenue

$986M84%

Product

$153M13%

Royalty

$36M3%

PTCT Q1 2025 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena